PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27435324-14	2016	CONCLUSION: The long-term treatment of PBC patients with fenofibrate as an adjunct to UDCA is safe and effective in improving ALP, but the treatment did not significantly reduce the estimated probability of liver-related death or need for liver transplantation.	Fenofibrate	57-68	ATHS	Homo sapiens	126-129	
10634964-7	1999	CONCLUSIONS: Micronised fenofibrate therapy in patients with Type 2 diabetes improved an establisheded ALP resulting in a more favourable lipid and LDL subfraction profile.	Fenofibrate	24-35	ATHS	Homo sapiens	103-106	
34697277-7	2021	Results: Among patients with aPBC treated with UDCA and fenofibrate, the ALP, GGT, and serum IgM levels decreased significantly (p<0.0001) over 48 weeks.	Fenofibrate	56-67	ATHS	Homo sapiens	73-76	
32480421-4	2020	When fenofibrate was added to Ursodiol therapy there was a significant reduction and in some cases normalization of serum ALP, ALT, and AST abnormalities, as well as pro-inflammatory cytokines.	Fenofibrate	5-16	ATHS	Homo sapiens	122-125